ASCO 2009: Experimental Targeted Therapy Vandetanib Improves Progression-Free Survival in Patients with Advanced Non-Small Cell Lung CancerThe results of an international trial have shown that adding the experimental targeted therapy vandetanib (Zactima)to docetaxel improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC)whose disease has progressed after first-line treatment. This is the first phase III study to show that adding atargeted therapy to second-line chemotherapy with docetaxel results in a clinical benefit for patients with advancedNSCLC. It is also the first phase III trial of vandetanib for NSCLC, which is being evaluated for certain types ofthyroid cancer as well.